Detection of impending graft rejection and relapse by lineage-specific chimerism analysis.
Molecular surveillance of hematopoietic chimerism has become part of the routine diagnostic program in patients after allogeneic stem cell transplantation. Chimerism testing permits early prediction and documentation of successful engraftment, and facilitates early detection of impending graft rejection. In patients transplanted for treatment of malignant hematological disorders, monitoring of chimerism can provide an early indication of incipient disease relapse. The investigation of chimerism has therefore become an indispensable tool for the management of patients during the posttransplant period. Growing use of nonmyeloablative conditioning, which is associated with prolonged duration of mixed hematopoietic chimerism, has further increased the clinical importance of chimerism analysis. At present, the most commonly used technical approach to the investigation of chimerism is microsatellite analysis by PCR. The investigation of chimerism within specific leukocyte subsets isolated from peripheral blood or bone marrow samples by flow-sorting or magnetic beads-based techniques provides more specific information on processes underlying the dynamics of donor/recipient chimerism. Moreover, cell subset-specific analysis permits the assessment of impending complications at a significantly higher sensitivity, thus providing a basis for earlier treatment decisions.
Children's Cancer Institute, St. Anna Children's Hospital, Vienna, Austria.
Thomas
T
Lion
D019070:Cell Lineage / Q000235:genetics / Q000276:immunology*; D003581:Cytodiagnosis / Q000379:methods*; D004247:DNA / Q000302:isolation & purification; D019075:Electrophoresis, Capillary / Q000379:methods; D005434:Flow Cytometry / Q000379:methods; D006084:Graft Rejection / Q000175:diagnosis*; D006801:Humans; D016130:Immunophenotyping / Q000379:methods; D016131:Lymphocyte Subsets / Q000166:cytology / Q000276:immunology; D018895:Microsatellite Repeats; D015166:Monitoring, Immunologic / Q000379:methods*; D016133:Polymerase Chain Reaction / Q000379:methods; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D012008:Recurrence; D018183:Transplantation Chimera / Q000235:genetics / Q000276:immunology*
D004247:DNA